A high-growth biotech with 144% year-over-year revenue expansion, elite growth-plus-profitability metrics, and wide competitive advantages, but persistent questions about cash conversion quality and a history of large earnings misses temper the case despite a favorable 2.9-to-1 risk/reward and 20% upside to the analyst target.
Thesis pillars
- Elite Growth And Moat→Stable
- Free Cash Flow Conversion Gap→Stable
- Earnings Track Record Volatile→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026
Ascendis Pharma A/S (ASND) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $249.55, but acceptable to hold if already in. Reasons: Thin upside margin: 9.4%; Consecutive earnings misses (2).
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency;... Read more
Hold if already holding. Not a fresh buy at $249.55, but acceptable to hold if already in. Reasons: Thin upside margin: 9.4%; Consecutive earnings misses (2). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Score 6.9/10, high confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Ascendis Pharma A/S
Latest news
- NEWS Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon(R) CNP (Navepegritide) at ISDS — marketscreener.com positive
- NEWS Ascendis Pharma Earnings Call Highlights Blockbuster Momentum - The Globe and Mail — The Globe and Mail positive
- NEWS Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk - Moomoo — Moomoo negative
- NEWS Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk - moomoo.com — moomoo.com negative
- NEWS ASND (Ascendis) edges higher post Q4 2025 results, with 98 percent revenue growth offsetting steep EPS miss. - Operating — Cổng thông tin điện tử Tỉnh Sơn La negative
Generated 2026-10-29T11:08:50Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $249.55, but acceptable to hold if already in. Reasons: Thin upside margin: 9.4%; Consecutive earnings misses (2). Chart setup: No clear chart pattern; technical signals are mixed. Wide-moat business. Accumulate on weakness. | News modifier -1 (STRONG_BUY_WAIT → HOLD_IF_HOLDING) Analyst target $272.91 (+9.4%), stop $237.91 (−4.9%), A.R:R 0.8:1. Score 6.9/10, high confidence.
Analyst target: $272.91 (+9.4% upside). Analyst target $272.91 (+9.4%), stop $237.91 (−4.9%), A.R:R 0.8:1. Stop-loss: $237.91.
Thin upside margin: 9.4%; Consecutive earnings misses (2); Overbought (RSI 82).
Ascendis Pharma A/S trades at a P/E of 19.1 (forward 25.0). TrendMatrix value score: 4.7/10. Verdict: Hold.
28 analysts cover ASND with a consensus score of 4.4/5. Average price target: $303.
What does Ascendis Pharma A/S do?Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for...
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.